证券代码：300642 证券简称：透景生命 公告编号：2025-061 上海透景生命科技股份有限公司 关于调整回购股份价格上限的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、为保障回购股份方案顺利实施，本次回购股份价格上限将由 15.85 元/ 股（含）调整为 29.34 元/股（含），该价格未超过董事会审议通过《关于调整 回购股份价格上限的议案》决议前 30 个交易日公司股票交易均价的 150%。 2、除上述调整回购股份价格上限外，回购股份方案的其他内容不变。 上海透景生命科技股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开第四届董事会第十二次会议，审议通过了《关于调整回购股份价格上限的 议案》。现将相关情况公告如下： 一、回购股份的基本情况 公司于 2025 年 4 月 8 日召开第四届董事会第八次会议，审议通过了《关于 以集中竞价交易方式回购公司股份的议案》。本次回购的股份用于股权激励或员 工持股计划，用于回购股份的资金总额不低于人民币 2,000 万元（含）且不超过 人民币 4,000 万元（含），回购 ...

上海透景生命科技股份有限公司 2025 年半年度报告全文 上海透景生命科技股份有限公司 2025 年半年度报告 公告编号：2025-058 2025 年 08 月 1 上海透景生命科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人姚见儿、主管会计工作负责人李松涛及会计机构负责人(会计 主管人员)李松涛声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来计划等前瞻性陈述的，均不构成公司对投资者的 实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且应当理解 计划、预测与承诺之间的差异。 公司在本报告第三节"管理层讨论与分析"之"十、公司面临的风险和 应对措施"中描述了公司经营中可能存在的风险及应对措施，敬请投资者注 意并仔细阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | | 2 | | ...

8月25日，透景生命盘中上涨9.28%，截至13:29，报28.38元/股，成交5.25亿元，换手率14.3%，总市值 46.13亿元。 资料显示，上海透景生命科技股份有限公司位于上海市浦东新区汇庆路412号，公司主要从事高端体外 诊断产品的研发、生产、推广和销售，以流式荧光技术、化学发光技术、多重荧光PCR技术和液相色谱 串联质谱技术为主要技术平台，主要应用方向包括肿瘤全程监测、自身免疫、心血管疾病、病原体感染 及生殖健康等。至今，公司已累计获得近300项医疗器械注册证，并于2017年成功上市，股票代码为 300642。 截至3月31日，透景生命股东户数1.7万，人均流通股8081股。 2025年1月-3月，透景生命实现营业收入7489.31万元，同比减少19.53%；归属净利润47.17万元，同比增 长110.51%。 ...

透景生命8月22日晚间发布公告称，上海透景生命科技股份有限公司的全资子公司江西透景生命科技有 限公司于近日取得江西省药品监督管理局颁发的2项医疗器械注册证。包括"维生素B12测定试剂盒（化 学发光免疫分析法）"等产品。 （文章来源：每日经济新闻） ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of the company, Transgenomic Life, within the medical device industry, noting its significant price-to-earnings (PE) ratio and market capitalization [1][2] - As of August 22, the company's stock closed at 25.97 yuan, reflecting a 7.67% increase, with a rolling PE ratio of 106.89, marking a new low in 822 days and a total market value of 4.22 billion yuan [1] - The average PE ratio for the medical device industry is 56.95, with a median of 40.49, positioning Transgenomic Life at the 106th rank within the industry [1][2] Group 2 - The company reported a revenue of 74.89 million yuan for Q1 2025, representing a year-on-year decrease of 19.53%, while net profit was 471,700 yuan, showing a significant increase of 110.51%, with a gross margin of 63.66% [1] - In terms of capital flow, on August 22, the company experienced a net inflow of 57.29 million yuan, with a total inflow of 158.99 million yuan over the past five days [1] - The company is actively involved in various health-themed public welfare activities and has received multiple awards for its social responsibility efforts, including the "Social Public Welfare Award" from the China Cancer Foundation [1]

| 产品名称 | 注册证编号 | 注册证有效期 | 注册分类 | 预期用途 | | --- | --- | --- | --- | --- | | 维生素B12 测定试 剂盒（化学发光免 疫分析法） | 赣械注准 20252400165 | 2025 年 8 月 8 日至 2030 年 8 月 7 日 | 第二类体外 诊断试剂 | 用于体外定量检测人体血清 中的维生素B12（VitaminB12， VB12）含量。临床上用于维生 素B12 缺乏相关疾病的辅助诊 | | | | | | 断。 | | 叶 酸 测 定 试 剂 盒 （化学发光免疫分 | 赣械注准 20252400174 | 2025 年 8 月 18 日至 2030 年 8 | 第二类体外 诊断试剂 | 用于体外定量检测人体血清 中叶酸（维生素B9）含量。临 床上用于巨幼红细胞性贫血 | | 析法） | | 月 17 日 | | | | | | | | 的辅助诊断。 | 一、基本信息 证券代码：300642 证券简称：透景生命 公告编号：2025-054 上海透景生命科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of the company,透景生命, in the medical device industry, noting its significant increase in stock price and market capitalization [1] - As of August 20, the company's stock closed at 24.81 yuan, up 7.45%, with a rolling PE ratio of 102.12, marking a new low in 668 days, and a total market value of 4.033 billion yuan [1] - The average PE ratio in the medical device industry is 59.32, with a median of 39.97, placing 透景生命 at the 104th position in the industry ranking [1][2] Group 2 - The company reported a revenue of 74.8931 million yuan for Q1 2025, reflecting a year-on-year decrease of 19.53%, while net profit was 471,700 yuan, showing a year-on-year increase of 110.51%, with a gross margin of 63.66% [1] - The company is actively involved in various health-themed public welfare activities and has received multiple awards for its social responsibility efforts, including the "Social Public Welfare Award" from the China Cancer Foundation [1]

Market Performance - The monkeypox concept sector declined by 0.86%, ranking among the top losers in the market, with stocks like Fuyuan Pharmaceutical and Chengyi Pharmaceutical hitting the daily limit down [1] - Notable declines were observed in Wanfu Biology, Rejing Biology, and Zhongsheng Pharmaceutical, while 23 stocks within the sector saw price increases, with Toukeng Life, Chuangyuan Technology, and New Industry leading the gains at 7.45%, 3.96%, and 1.86% respectively [1][2] Capital Flow - The monkeypox concept sector experienced a net outflow of 1.624 billion yuan, with 61 stocks facing net outflows, and 11 stocks seeing outflows exceeding 50 million yuan [2] - The stock with the highest net outflow was Hanyu Pharmaceutical, with a net outflow of 212.3 million yuan, followed by Fuyuan Pharmaceutical, Wanfu Biology, and Zhongsheng Pharmaceutical with net outflows of 164.1 million yuan, 126 million yuan, and 120 million yuan respectively [2][3] Top Gainers and Losers - The top gainers in the monkeypox concept sector included Toukeng Life, which saw a net inflow of 24.68 million yuan, and Guoyao Modern with a net inflow of 2.185 million yuan [4] - Conversely, the top losers included Hanyu Pharmaceutical, Fuyuan Pharmaceutical, and Wanfu Biology, which all faced significant capital outflows [2][3]

证券之星消息，8月20日医疗器械板块较上一交易日上涨0.06%，济民健康领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。医疗器械板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603222 | 济民健康 | 11.86 | 10.02% | 164.39万 | | 18.28亿 | | 300642 | 透景生命 | 24.81 | 7.45% | 35.17万 | | 8.65 Z | | 688581 | 安杰思 | 87.93 | 6.07% | 2.57万 | | 2.20亿 | | 301093 | 华兰股份 | 34.04 | 4.58% | 13.19万 | | 4.45亿 | | 600645 | 中源协和 | 29.66 | 3.27% | 23.37万 | | ...

Group 1 - The medical device sector experienced a volatile pullback on August 19, with the medical device ETF (562600) declining by 2.13%. However, stocks such as Tsinghua Tongfang and Furuide surged to a 20% limit up, while Jimin Health and Blue Sail Medical reached a 10% limit up [1] - Over the past five trading days, there have been net inflows into the medical device ETF for four days, accumulating a total of 36.79 million yuan. In the last ten trading days, there were net inflows for eight days, totaling 52.49 million yuan [1] - On August 15, Hainan Province announced new policies to support the high-quality development of the biopharmaceutical industry, effective from September 13 for three years. The policies include a reward of up to 3% of actual sales for companies participating in national centralized procurement, with a maximum reward of 3 million yuan [1] Group 2 - The medical device ETF (562600) serves as a convenient tool for investors to capture growth opportunities in the medical device industry, tracking the CSI All Share Medical Device Index, which includes 100 representative listed companies in core medical fields [2] - The medical device industry accounts for a significant 89.34% of the index, indicating a high concentration that allows for precise capture of development dividends in the medical device sector [2]